Sol-Gel Technologies (SLGL) Non-Current Assets (2016 - 2026)
Sol-Gel Technologies (SLGL) reported Non-Current Assets of $2.8 million for Q1 2026, down 23.96% year-over-year from $3.6 million in Q1 2025, and down 6.28% quarter-over-quarter from $2.9 million in Q4 2025.
Sol-Gel Technologies (SLGL) Non-Current Assets (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Non-Current Assets data on file, last reported at $2.8 million in Q1 2026.
- Non-Current Assets for Q1 2026 came in at $2.8 million, down 23.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (down 23.96% YoY), and the FY2025 annual result was $2.9 million, down 35.27% from the prior year.
- Non-Current Assets declined to $2.8 million in Q1 2026 per SLGL's latest filing, from $2.9 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $9.3 million in Q1 2022 and troughed at $2.8 million in Q1 2026.
- A 5-year average of $4.5 million and a median of $3.7 million in 2022 frame the typical range for Non-Current Assets.
- On a YoY basis, Non-Current Assets climbed as much as 75.06% in 2022 and fell as far as 70.43% in 2022.
- A 5-year view of Non-Current Assets shows it stood at $3.6 million in 2022, then advanced by 15.31% to $4.1 million in 2023, then climbed by 10.46% to $4.6 million in 2024, then plunged by 35.27% to $2.9 million in 2025, then declined by 6.28% to $2.8 million in 2026.
- Business Quant data shows SLGL's Non-Current Assets at $2.8 million in Q1 2026, $2.9 million in Q4 2025, and $2.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 2.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.76 Mn |
| Dec 31, 2025 | 2.95 Mn |
| Sep 30, 2025 | 2.94 Mn |
| Jun 30, 2025 | 3.05 Mn |
| Mar 31, 2025 | 3.63 Mn |
| Dec 31, 2024 | 4.55 Mn |
| Sep 30, 2024 | 5.03 Mn |
| Jun 30, 2024 | 3.72 Mn |
| Mar 31, 2024 | 3.90 Mn |
| Dec 31, 2023 | 4.12 Mn |
| Sep 30, 2023 | 4.39 Mn |
| Jun 30, 2023 | 3.51 Mn |
| Mar 31, 2023 | 8.36 Mn |
| Dec 31, 2022 | 3.57 Mn |
| Sep 30, 2022 | 3.73 Mn |
| Jun 30, 2022 | 6.51 Mn |
| Mar 31, 2022 | 9.34 Mn |
| Dec 31, 2021 | 12.08 Mn |
| Sep 30, 2021 | 4.68 Mn |
| Jun 30, 2021 | 5.01 Mn |